Business
BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure
BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical C...
About this update from Carlyle Commodities Corp.
[{"type":"text","content":"\n \n \n \n BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries\n \n \n \n \n LONDON\n \n ,\n \n Nov. 8, 2021\n \n /CNW/ --\n \n Clarivate Plc\n \n (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. The new collaboration will leverage Clarivate Consulting Service's computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.\n \n \n \n \n \n \n \n \n \n Drug repurposing evaluates new uses, outside of the original clinical indication, for therapeutics approved by the U.S. Food and Drug Administration (FDA) or in late-stage development. BARDA funding will aid in target identification and drug factor analyses to identify potential drugs for repurposing to treat chemical agent exposure. These drugs may affect biological pathways that are implicated in chemical agent exposure or in the body's response to it and may already treat analogous diseases with similar biology but different causes. Such drugs, particularly when highly available in our pharmaceutical supply chain, may be studied and developed in an accelerated manner to provide reserve capacity in response to exposure events.\n \n \n Many chemical threats exist that can inflict injuries rapidly, and MCMs must be readily available to mitigate these risks. With conventional drug discovery involving costly and lengthy studies, using machine learning and artificial intelligence (A...